nach oben

BioDrugs

Erschienen in:

01.10.2013 | Current Opinion

Genome-Based Bacterial Vaccines: Current State and Future Outlook

verfasst von: Alexandra Schubert-Unkmeir, Myron Christodoulides

Erschienen in: BioDrugs | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Genome-based reverse vaccinology (RV) is a multi-step experimental strategy which starts from in silico analysis of whole genome sequences, from which vaccine candidates can be selected by using bioinformatic algorithms to identify putative protective antigens. In this review, we examine the current state of genome-based RV-engineered vaccines and future applications. The first product of genome-based RV is Bexsero^®, a vaccine developed for preventing Neisseria meningitidis serogroup B infection, and the strategy is currently being used for the development of new vaccines for other obdurate and emerging bacterial diseases. Improved sequencing technologies and the ongoing whole-genome sequence analyses of helminths, protozoa, and ectoparasites also currently serve as a basis for an RV strategy to produce new potential vaccines against eukaryotic pathogens. We also highlight an emerging approach—structure-based vaccinology—that exploits the information derived from the determined three-dimensional structures of vaccine candidates. Regardless, genome-based RV and other vaccine discovery platforms still depend on empirical experimental science to glean, from the hundreds of identified antigens from any one pathogen, those that should be combined to produce an effective vaccine.

Hammarsten JF, Tattersall W, Hammarsten JE. Who discovered smallpox vaccination? Edward Jenner or Benjamin Jesty? Trans Am Clin Climatol Assoc. 1979;90:44–55.PubMed

Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc Bayl Univ Med Cent. 2005;18(1):21–5.PubMed

Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat Rev Microbiol. 2011;9(12):889–93.PubMedCrossRef

Telford JL. Bacterial genome variability and its impact on vaccine design. Cell Host Microbe. 2008;3(6):408–16.PubMedCrossRef

Lipsitch M, O’Hagan JJ. Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface. 2007;4(16):787–802.PubMedCrossRef

Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995;269(5223):496–512.PubMedCrossRef

Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816–20.PubMedCrossRef

Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445–50.PubMedCrossRef

Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001;19(17–19):2688–91.PubMedCrossRef

10.

Van Regenmortel MH. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol. 2012;3:194.PubMed

11.

Van Regenmortel MH. Two meanings of reverse vaccinology and the empirical nature of vaccine science. Vaccine. 2011;29(45):7875.PubMedCrossRef

12.

Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol. 2006;24:739–69.PubMedCrossRef

13.

Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol. 2010;22(3):358–66.PubMedCrossRef

14.

Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324(5924):246–51.PubMedCrossRef

15.

Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128–131A complex. J Virol. 2010;84(2):1005–13.PubMedCrossRef

16.

Adu-Bobie J, Capecchi B, Serruto D, Rappuoli R, Pizza M. Two years into reverse vaccinology. Vaccine. 2003;21(7–8):605–10.PubMedCrossRef

17.

Johnson DA. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr Top Med Chem. 2008;8(2):64–79.PubMedCrossRef

18.

Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31(1):3–14.PubMedCrossRef

19.

Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63.PubMedCrossRef

20.

Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987;138(12):4402–7.PubMed

21.

Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355–7.PubMedCrossRef

22.

Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511–20.PubMedCrossRef

23.

Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195–207 (discussion 8–10).

24.

Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz. 1999;94(4):433–40.

25.

de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340(8827):1074–8.PubMedCrossRef

26.

Oster P, Lennon D, O’Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23(17–18):2191–6.PubMedCrossRef

27.

Kelly C, Arnold R, Galloway Y, O’Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol. 2007;166(7):817–23.PubMedCrossRef

28.

Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000;287(5459):1809–15.PubMedCrossRef

29.

Palumbo E, Fiaschi L, Brunelli B, Marchi S, Savino S, Pizza M. Antigen identification starting from the genome: a “Reverse Vaccinology” approach applied to MenB. Methods Mol Biol. 2012;799:361–403.PubMedCrossRef

30.

Vermont C, van den Dobbelsteen G. Neisseria meningitidis serogroup B: laboratory correlates of protection. FEMS Immunol Med Microbiol. 2002;34(2):89–96.PubMedCrossRef

31.

Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A. 2010;107(8):3770–5.PubMedCrossRef

32.

Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177(1):501–10.PubMed

33.

Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol. 2006;176(12):7566–75.PubMed

34.

Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, Taddei A, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol. 2005;55(3):687–98.PubMedCrossRef

35.

Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Arico B, Capecchi B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 2002;195(11):1445–54.PubMedCrossRef

36.

Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006;103(29):10834–9.PubMedCrossRef

37.

Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–97.PubMedCrossRef

38.

Panatto D, Amicizia D, Lai PL, Gasparini R. Neisseria meningitidis B vaccines. Expert Rev Vaccines. 2011;10(9):1337–51.PubMedCrossRef

39.

Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71–9.PubMed

40.

O’Hallahan J, McNicholas A, Galloway Y, O’Leary E, Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J. 2009;122(1291):48–59.PubMed

41.

Gorringe AR, Pajon R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother. 2012;8(2):174–83.PubMedCrossRef

42.

Wetzler LM. Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines. Ann N Y Acad Sci. 1994;730:367–70.PubMedCrossRef

43.

Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011;11(7):969–85.PubMedCrossRef

44.

Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617–24.PubMedCrossRef

45.

Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–82.PubMedCrossRef

46.

Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127–37.PubMedCrossRef

47.

Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825–35.PubMedCrossRef

48.

Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19(10):1609–17.PubMedCrossRef

49.

Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013. doi:10.1016/S1473-3099(13)70006-9.

50.

Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45):19490–5.PubMedCrossRef

51.

Boccadifuoco G, Brunelli B, Pizza MG, Giuliani MM. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine. J Prev Med Hyg. 2012;53(2):56–60.PubMed

52.

Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088–100.PubMedCrossRef

53.

Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2013;32(4):364–71.

54.

Melin P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies. Clin Microbiol Infect. 2011;17(9):1294–303.PubMed

55.

Rodriguez-Granger J, Alvargonzalez JC, Berardi A, Berner R, Kunze M, Hufnagel M, et al. Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project. Eur J Clin Microbiol Infect Dis. 2012;31(9):2097–104.PubMedCrossRef

56.

Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child. 2003;88(5):375–8.PubMedCrossRef

57.

Tettelin H, Masignani V, Cieslewicz MJ, Donati C, Medini D, Ward NL, et al. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial “pan-genome”. Proc Natl Acad Sci U S A. 2005;102(39):13950–5.PubMedCrossRef

58.

Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, et al. Identification of a universal Group B Streptococcus vaccine by multiple genome screen. Science. 2005;309(5731):148–50.PubMedCrossRef

59.

Lauer P, Rinaudo CD, Soriani M, Margarit I, Maione D, Rosini R, et al. Genome analysis reveals pili in Group B Streptococcus. Science. 2005;309(5731):105.PubMedCrossRef

60.

Telford JL, Barocchi MA, Margarit I, Rappuoli R, Grandi G. Pili in gram-positive pathogens. Nat Rev Microbiol. 2006;4(7):509–19.PubMedCrossRef

61.

O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902.PubMedCrossRef

62.

Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30(1):122–40.PubMedCrossRef

63.

Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100–21.PubMedCrossRef

64.

Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31(1):72–7.PubMedCrossRef

65.

Weckx LY, Thompson A, Berezin EN, de Faria SM, da Cunha CA, Pride M, et al. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012;30(52):7566–72.PubMedCrossRef

66.

Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31(5):501–8.PubMedCrossRef

67.

Icardi G, Sticchi L, Bagnasco A, Iudici R, Durando P. Pneumococcal vaccination in adults: rationale, state of the art and perspectives. J Prev Med Hyg. 2012;53(2):78–84.PubMed

68.

Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol. 2011;23(3):407–13.PubMedCrossRef

69.

Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. Vaccine. 2007;25(16):2963–73.PubMedCrossRef

70.

Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244–56.PubMedCrossRef

71.

Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, Choi GH, et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun. 2001;69(3):1593–8.PubMedCrossRef

72.

Gianfaldoni C, Censini S, Hilleringmann M, Moschioni M, Facciotti C, Pansegrau W, et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun. 2007;75(2):1059–62.PubMedCrossRef

73.

Harfouche C, Filippini S, Gianfaldoni C, Ruggiero P, Moschioni M, Maccari S, et al. RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect Immun. 2012;80(1):451–60.PubMedCrossRef

74.

Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev. 1995;8(4):451–61.PubMed

75.

Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun. 2002;70(1):368–79.PubMedCrossRef

76.

Thorpe C, Edwards L, Snelgrove R, Finco O, Rae A, Grandi G, et al. Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection. Vaccine. 2007;25(12):2252–60.PubMedCrossRef

77.

Manque PA, Tenjo F, Woehlbier U, Lara AM, Serrano MG, Xu P, et al. Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. Clin Vaccine Immunol. 2011;18(11):1796–802.PubMedCrossRef

78.

Gan W, Zhao G, Xu H, Wu W, Du W, Huang J, et al. Reverse vaccinology approach identify an Echinococcus granulosus tegumental membrane protein enolase as vaccine candidate. Parasitol Res. 2010;106(4):873–82.PubMedCrossRef

79.

Schroeder J, Aebischer T. Vaccines for leishmaniasis: from proteome to vaccine candidates. Hum Vaccin. 2011;7(Suppl):10–5.PubMedCrossRef

80.

John L, John GJ, Kholia T. A reverse vaccinology approach for the identification of potential vaccine candidates from Leishmania spp. Appl Biochem Biotechnol. 2012;167(5):1340–50.PubMedCrossRef

81.

Zhao BP, Chen L, Zhang YL, Yang JM, Jia K, Sui CY, et al. In silico prediction of binding of promiscuous peptides to multiple MHC class-II molecules identifies the Th1 cell epitopes from secreted and transmembrane proteins of Schistosoma japonicum in BALB/c mice. Microbes Infect. 2011;13(7):709–19.PubMedCrossRef

82.

Chaudhuri R, Ahmed S, Ansari FA, Singh HV, Ramachandran S. MalVac: database of malarial vaccine candidates. Malar J. 2008;7:184.PubMedCrossRef

83.

Snelling WJ, Xiao L, Ortega-Pierres G, Lowery CJ, Moore JE, Rao JR, et al. Cryptosporidiosis in developing countries. J Infect Dev Ctries. 2007;1(3):242–56.PubMed

84.

Shirley DA, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis. Curr Opin Infect Dis. 2012;25(5):555–63.PubMedCrossRef

85.

Xu P, Widmer G, Wang Y, Ozaki LS, Alves JM, Serrano MG, et al. The genome of Cryptosporidium hominis. Nature. 2004;431(7012):1107–12.PubMedCrossRef

86.

Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, et al. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science. 2004;304(5669):441–5.PubMedCrossRef

87.

Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114(1):1–16.PubMedCrossRef

88.

Olson PD, Zarowiecki M, Kiss F, Brehm K. Cestode genomics—progress and prospects for advancing basic and applied aspects of flatworm biology. Parasite Immunol. 2012;34(2–3):130–50.PubMedCrossRef

89.

Tsai IJ, Zarowiecki M, Holroyd N, Garciarrubio A, Sanchez-Flores A, Brooks KL, et al. The genomes of four tapeworm species reveal adaptations to parasitism. Nature. 2013. doi:10.1038/nature12031.

90.

Doytchinova IA, Flower DR. Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. Vaccine. 2007;25(5):856–66.PubMedCrossRef

91.

Maritz-Olivier C, van Zyl W, Stutzer C. A systematic, functional genomics, and reverse vaccinology approach to the identification of vaccine candidates in the cattle tick, Rhipicephalus microplus. Ticks Tick Borne Dis. 2012;3(3):179–87.PubMedCrossRef

92.

Stephens DS. Prevention of serogroup B meningococcal disease. Lancet. 2012;379(9816):592–4.PubMedCrossRef

93.

Scarselli M, Arico B, Brunelli B, Savino S, Di Marcello F, Palumbo E, et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med. 2011;3(91):91ra62.PubMedCrossRef

94.

Nuccitelli A, Cozzi R, Gourlay LJ, Donnarumma D, Necchi F, Norais N, et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci U S A. 2011;108(25):10278–83.PubMedCrossRef

95.

Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics. 2006;6(11):3400–13.PubMedCrossRef

96.

Mendum TA, Newcombe J, McNeilly CL, McFadden J. Towards the immunoproteome of Neisseria meningitidis. PLoS One. 2009;4(6):e5940.PubMedCrossRef

97.

Williams JN, Skipp PJ, O’Connor CD, Christodoulides M, Heckels JE. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect Immun. 2009;77(11):5080–9.PubMedCrossRef

98.

Hedman AK, Li MS, Langford PR, Kroll JS. Transcriptional profiling of serogroup B Neisseria meningitidis growing in human blood: an approach to vaccine antigen discovery. PLoS One. 2012;7(6):e39718.PubMedCrossRef

99.

Echenique-Rivera H, Muzzi A, Del Tordello E, Seib KL, Francois P, Rappuoli R, et al. Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog. 2011;7(5):e1002027.PubMedCrossRef

100.

Christensen H, Trotter CL, Hickman M, Edmunds WJ. Modelling the cost-effectiveness of new meningococcal vaccines in England. International pathogenic neisseria conference, Banff (2010).

101.

Goure J, Findlay WA, Deslandes V, Bouevitch A, Foote SJ, MacInnes JI, et al. Microarray-based comparative genomic profiling of reference strains and selected Canadian field isolates of Actinobacillus pleuropneumoniae. BMC Genomics. 2009;10:88.PubMedCrossRef

102.

Palmer GH, Brown WC, Noh SM, Brayton KA. Genome-wide screening and identification of antigens for rickettsial vaccine development. FEMS Immunol Med Microbiol. 2012;64(1):115–9.PubMedCrossRef

103.

Song Y, La T, Phillips ND, Bellgard MI, Hampson DJ. A reverse vaccinology approach to swine dysentery vaccine development. Vet Microbiol. 2009;137(1–2):111–9.PubMedCrossRef

104.

He Y. Analyses of Brucella pathogenesis, host immunity, and vaccine targets using systems biology and bioinformatics. Front Cell Infect Microbiol. 2012;2:2.PubMedCrossRef

105.

Zhang M, Wu H, Li X, Yang M, Chen T, Wang Q, et al. Edwardsiella tarda flagellar protein FlgD: a protective immunogen against edwardsiellosis. Vaccine. 2012;30(26):3849–56.PubMedCrossRef

106.

Liebenberg J, Pretorius A, Faber FE, Collins NE, Allsopp BA, van Kleef M. Identification of Ehrlichia ruminantium proteins that activate cellular immune responses using a reverse vaccinology strategy. Vet Immunol Immunopathol. 2012;145(1–2):340–9.PubMedCrossRef

107.

Sebatjane SI, Pretorius A, Liebenberg J, Steyn H, Van Kleef M. In vitro and in vivo evaluation of five low molecular weight proteins of Ehrlichia ruminantium as potential vaccine components. Vet Immunol Immunopathol. 2010;137(3–4):217–25.PubMedCrossRef

108.

Nesta B, Spraggon G, Alteri C, Moriel DG, Rosini R, Veggi D, et al. FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio. 2012;3(2). doi:10.1128/mBio.00010-12.

109.

Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A. 2010;107(20):9072–7.PubMedCrossRef

110.

Hong M, Ahn J, Yoo S, Hong J, Lee E, Yoon I, et al. Identification of novel immunogenic proteins in pathogenic Haemophilus parasuis based on genome sequence analysis. Vet Microbiol. 2011;148(1):89–92.PubMedCrossRef

111.

Umamaheswari A, Pradhan D, Hemanthkumar M. Computer aided subunit vaccine design against pathogenic Leptospira serovars. Interdiscip Sci. 2012;4(1):38–45.PubMedCrossRef

112.

Yang HL, Zhu YZ, Qin JH, He P, Jiang XC, Zhao GP, et al. In silico and microarray-based genomic approaches to identifying potential vaccine candidates against Leptospira interrogans. BMC Genomics. 2006;7:293.PubMedCrossRef

113.

Hatfaludi T, Al-Hasani K, Gong L, Boyce JD, Ford M, Wilkie IW, et al. Screening of 71 P. multocida proteins for protective efficacy in a fowl cholera infection model and characterization of the protective antigen PlpE. PLoS One. 2012;7(7):e39973.PubMedCrossRef

114.

Ross BC, Czajkowski L, Hocking D, Margetts M, Webb E, Rothel L, et al. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine. 2001;19(30):4135–42.PubMedCrossRef

115.

Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, Manetti AG, et al. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci U S A. 2005;102(43):15641–6.PubMedCrossRef

116.

Rodriguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol. 2006;24(2):191–7.PubMedCrossRef

117.

Ge X, Kitten T, Munro CL, Conrad DH, Xu P. Pooled protein immunization for identification of cell surface antigens in Streptococcus sanguinis. PLoS One. 2010;5(7):e11666.PubMedCrossRef

118.

Liu L, Cheng G, Wang C, Pan X, Cong Y, Pan Q, et al. Identification and experimental verification of protective antigens against Streptococcus suis serotype 2 based on genome sequence analysis. Curr Microbiol. 2009;58(1):11–7.PubMedCrossRef

119.

Graham SP, Honda Y, Pelle R, Mwangi DM, Glew EJ, de Villiers EP, et al. A novel strategy for the identification of antigens that are recognised by bovine MHC class I restricted cytotoxic T cells in a protozoan infection using reverse vaccinology. Immunome Res. 2007;3:2.PubMedCrossRef

Titel: Genome-Based Bacterial Vaccines: Current State and Future Outlook
verfasst von: Alexandra Schubert-Unkmeir
Myron Christodoulides
Publikationsdatum: 01.10.2013
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 5/2013
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.1007/s40259-013-0034-5

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Genome-Based Bacterial Vaccines: Current State and Future Outlook

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

A Review of Dendritic Cell Therapy for Cancer: Progress and Challenges

The Th17 Pathway as a Therapeutic Target in Rheumatoid Arthritis and Other Autoimmune and Inflammatory Disorders

Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies

Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane